Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Presentations

At Sygnature Discovery we are committed to adding value to our client’s programs by providing relevant and innovative solutions to their discovery programs. Our experienced scientists regularly engage with the drug discovery community to share our recent advances, expert opinion and updates on our successful collaborations, helping Sygnature to remain at the leading edge of scientific advances. Download our most recent scientific presentations here.

Clear search

A Breath of Fresh Air: Delivering Novel Respiratory Syncytial Virus (RSV) Inhibitors

Abstract Pulmocide Ltd., a VC-funded biotechnology company, was founded to discover more effective and safer inhaled treatments for serious viral and fungal infections of the respiratory tract. Human respiratory syncytial virus (hRSV) is the...

FIND OUT MORE

Efficient fragment library screening at Sygnature Discovery by SPR and MST

Abstract Sygnature Discovery engages with clients in a range of integrated drug discovery projects.  Efficient hit finding approaches are critical to the early stages of these programmes. Fragment screening represents an extremely efficient approach...

FIND OUT MORE

Smarter IDO inhibitor profiling using biophysical, biochemical and cellular target engagement approaches

Abstract In small molecule drug discovery for intracellular enzyme inhibitors, it is essential to have an efficient and informative hit profiling strategy in place that ideally measures target engagement in situ. Using inhibitors of...

FIND OUT MORE
MORE...

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.